Literature DB >> 16867224

Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.

Karl-Ludwig Schaefer1, Kristin Brachwitz, Yvonne Braun, Raihanatou Diallo, Daniel H Wai, Susanne Zahn, Dominik T Schneider, Cornelius Kuhnen, Arabel Vollmann, Gero Brockhoff, Helmut E Gabbert, Christopher Poremba.   

Abstract

Clear cell sarcoma of soft tissue (CCSST) represents a highly malignant tumor of the musculoskeletal system that is characterized by the chromosomal translocation t(12;22)(q13;q12) of the Ewing sarcoma gene (EWSR1) and activating transcription factor 1 (ATF1). In a former microarray expression study, we identified ERBB3, a member of the epidermal growth factor receptor (EGFR) family, as a promising new diagnostic marker in the differential diagnosis of CCSST. Here we show that, besides ErbB3, all CCSST cell lines (n = 8) also express the ErbB2 receptor or the ErbB4 receptor, representing an adequate coreceptor of ErbB3. The phosphorylation status of ErbB3 revealed these receptor pairs to be either constitutively activated in CCSST cells with high neuregulin-1 (NRG1) expression (n = 4) or activatable by exogenic NRG1 in cells showing low amounts of NRG1 mRNA (n = 4). Exogenous NRG1 stimulated the growth of a subset of CCSST cells but did not affect the kinetics of another subset. This difference was not strictly dependent on endogenous NRG1 expression; however, the growth-inhibiting effect of the pan-ErbB tyrosine kinase inhibitor CI-1033 or PD158780 clearly correlated with NRG1 expression indicating an autocrine growth stimulation loop which may constitute an interesting target of new therapeutic strategies in this tumor entity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16867224      PMCID: PMC1601931          DOI: 10.1593/neo.06238

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  30 in total

Review 1.  The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?

Authors:  John G Shelton; Linda S Steelman; Steve L Abrams; Fred E Bertrand; Richard A Franklin; Martin McMahon; James A McCubrey
Journal:  Expert Opin Ther Targets       Date:  2005-10       Impact factor: 6.902

Review 2.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

Authors:  Y Yarden
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

3.  Population-based genetic alterations in Ewing's tumors from Japanese and European Caucasian patients.

Authors:  T Ozaki; K-L Schaefer; D Wai; R Yokoyama; S Ahrens; R Diallo; T Hasegawa; T Shimoda; S Hirohashi; A Kawai; N Naito; Y Morimoto; H Inoue; W Boecker; H Juergens; W Winkelmann; B Dockhorn-Dworniczak; C Poremba
Journal:  Ann Oncol       Date:  2002-10       Impact factor: 32.976

4.  Genetic analysis of mediastinal nonseminomatous germ cell tumors in children and adolescents.

Authors:  Dominik T Schneider; Amy E Schuster; Michael K Fritsch; Gabriele Calaminus; Ulrich Göbel; Dieter Harms; Stephen Lauer; Thomas Olson; Elizabeth J Perlman
Journal:  Genes Chromosomes Cancer       Date:  2002-05       Impact factor: 5.006

Review 5.  Clear cell sarcoma: the Roswell Park experience.

Authors:  J W Finley; B Hanypsiak; B McGrath; W Kraybill; J F Gibbs
Journal:  J Surg Oncol       Date:  2001-05       Impact factor: 3.454

6.  Characterization of the malignant melanoma of soft-parts cell line GG-62 by expression analysis using DNA microarrays.

Authors:  Karl-Ludwig Schaefer; Daniel H Wai; Christopher Poremba; Eberhard Korsching; Frans van Valen; Toshifumi Ozaki; Werner Boecker; Barbara Dockhorn-Dworniczak
Journal:  Virchows Arch       Date:  2001-12-04       Impact factor: 4.064

7.  Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells.

Authors:  C Ricci; L Landuzzi; I Rossi; C De Giovanni; G Nicoletti; A Astolfi; S Pupa; S Menard; K Scotlandi; P Nanni; P L Lollini
Journal:  Int J Cancer       Date:  2000-07-01       Impact factor: 7.396

8.  Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma.

Authors:  Dafydd G Thomas; Thomas J Giordano; Donita Sanders; J Sybil Biermann; Laurence Baker
Journal:  Clin Cancer Res       Date:  2002-03       Impact factor: 12.531

9.  Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays.

Authors:  Daniel H Wai; Karl-Ludwig Schaefer; Alexander Schramm; Eberhard Korsching; Frans Van Valen; Toshifumi Ozaki; Werner Boecker; Lothar Schweigerer; Barbara Dockhorn-Dworniczak; Christopher Poremba
Journal:  Int J Oncol       Date:  2002-03       Impact factor: 5.650

10.  Clear cell sarcoma of tendons and aponeuroses in pediatric patients: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group.

Authors:  Andrea Ferrari; Michela Casanova; Gianni Bisogno; Adrian Mattke; Cristina Meazza; Lorenza Gandola; Guido Sotti; Giovanni Cecchetto; Dieter Harms; Eva Koscielniak; Jorn Treuner; Modesto Carli
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

View more
  11 in total

1.  Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.

Authors:  Chunrong Li; Toni M Brand; Mari Iida; Shyhmin Huang; Eric A Armstrong; Albert van der Kogel; Deric L Wheeler
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

2.  HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Authors:  Marcia R Campbell; Dhara Amin; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.

Authors:  Isabelle Messner; Giuseppe Cadeddu; Wolfgang Huckenbeck; Helen J Knowles; Helmut E Gabbert; Stephan E Baldus; Karl-Ludwig Schaefer
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-27       Impact factor: 4.553

4.  Neuregulin 1 (NRG1) fusion-positive high-grade spindle cell sarcoma: A distinct group of soft tissue tumors with metastatic potential.

Authors:  Josephine K Dermawan; Youran Zou; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2021-11-30       Impact factor: 5.006

5.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

6.  Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.

Authors:  Jenny Potratz; Amelie Tillmanns; Philipp Berning; Eberhard Korsching; Christiane Schaefer; Birgit Lechtape; Carolin Schleithoff; Rebekka Unland; Karl-Ludwig Schäfer; Carsten Müller-Tidow; Heribert Jürgens; Uta Dirksen
Journal:  Mol Oncol       Date:  2015-12-20       Impact factor: 6.603

Review 7.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

8.  A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptor.

Authors:  Aislyn D W Boran; Joseph Seco; Vinodh Jayaraman; Gomathi Jayaraman; Shan Zhao; Sushmitha Reddy; Yibang Chen; Ravi Iyengar
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

9.  deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data.

Authors:  Andrew McPherson; Fereydoun Hormozdiari; Abdalnasser Zayed; Ryan Giuliany; Gavin Ha; Mark G F Sun; Malachi Griffith; Alireza Heravi Moussavi; Janine Senz; Nataliya Melnyk; Marina Pacheco; Marco A Marra; Martin Hirst; Torsten O Nielsen; S Cenk Sahinalp; David Huntsman; Sohrab P Shah
Journal:  PLoS Comput Biol       Date:  2011-05-19       Impact factor: 4.475

Review 10.  The promise of anti-ErbB3 monoclonals as new cancer therapeutics.

Authors:  Luigi Aurisicchio; Emanuele Marra; Giuseppe Roscilli; Rita Mancini; Gennaro Ciliberto
Journal:  Oncotarget       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.